Cardiovascular Longevity

Cardiovascular disease is still the #1 cause of death worldwide — and the slope of risk steepens every decade after 40. Arterial stiffness rises. Endothelial nitric oxide production declines. Lipoproteins oxidise more readily. Mitochondrial efficiency in the cardiomyocytes that contract roughly 100,000 times a day drops. Subclinical inflammation creeps up. Blood pressure follows.

The supplement evidence in this category is unusually strong because cardiovascular endpoints are easy to measure: blood pressure, LDL particle number, triglycerides, hsCRP, arterial calcification (CAC score), flow-mediated dilation, ejection fraction, and hard outcomes like major adverse cardiovascular events (MACE) and all-cause mortality. A small group of compounds has moved those needles in repeated, large, well-designed human trials — many at FDA-approval-grade evidence levels.

The 30-second answer

Five mechanisms drive cardiovascular aging: (1) endothelial dysfunction (nitric oxide collapse), (2) arterial stiffness and calcification, (3) oxidised-LDL-driven atherogenesis, (4) mitochondrial bioenergetic decline in the heart, and (5) chronic low-grade inflammation. Six compounds with the deepest human-trial evidence address them: Omega-3 EPA/DHA (REDUCE-IT, JELIS, GISSI-Prevenzione), Vitamin D3 + K2 (MK-7) (Maresz 2015, Knapen 2015), Magnesium glycinate (Zhang 2016 meta-analysis, Kass 2012), Taurine (Singh 2023 Nature, Beyranvand 2011), CoQ10 (Q-SYMBIO, Mortensen 2014), and Spermidine (Eisenberg 2016 Nature Medicine, Kiechl 2018 AJCN). On top of those, TMG for homocysteine, Berberine for lipids, and a sirtuin/mitophagy layer (Resveratrol, Pterostilbene, Spermidine, NR, Quercetin, ALA, Curcumin, PQQ) for the cellular machinery that determines how long the system stays elastic.

• Foundation (everyone over 40): Omega-3 + D3+K2 + Magnesium. These three replicate across hundreds of cardiovascular trials and most adults are deficient in at least one.
• Add Taurine and CoQ10 if you're over 50, on a statin, or have any heart-failure family history. CoQ10 is mandatory on statins (statins deplete it directly via the mevalonate pathway).
• Layer Spermidine, TMG and a NAD+ precursor (NMN or NR) for the cellular-renewal layer that determines whether your vasculature stays elastic into your 70s and 80s.
• If lipids or glucose are off, add Berberine (AMPK pathway, comparable to metformin in head-to-head) or Curcumin (endothelial function, hsCRP).
• Time horizon: Magnesium and Omega-3 shift markers in 4–8 weeks. CoQ10 in 8–12 weeks. K2 arterial-calcification effects measured at 3 years (Knapen 2015). NAD+/sirtuin/spermidine endpoints accumulate over 6–12+ months.

Why the cardiovascular system ages — five mechanisms

1. Endothelial dysfunction (nitric oxide collapse)

The endothelium — the single-cell lining of every blood vessel — produces nitric oxide (NO) via endothelial nitric oxide synthase (eNOS). NO relaxes vascular smooth muscle, lowers blood pressure, suppresses platelet aggregation, and inhibits leukocyte adhesion. eNOS activity declines with age, with shear-stress loss (sedentary living), and with the accumulation of asymmetric dimethylarginine (ADMA), an endogenous eNOS inhibitor. Flow-mediated dilation (FMD) — the gold-standard endothelial measurement — drops roughly 0.21% per decade after 40 in healthy adults and faster with diabetes, hypertension, or smoking.

Targeted by: Omega-3 EPA/DHA (raises eNOS expression, lowers ADMA), Taurine (Beyranvand 2011 + Singh 2023, FMD restoration), Resveratrol (eNOS upregulator, Wallerath 2002), Magnesium Glycinate (vascular smooth-muscle relaxant), Curcumin (Akazawa 2012 FMD trial in postmenopausal women).

2. Arterial stiffness and calcification

Aortic pulse-wave velocity (PWV) — the speed a pressure wave travels down the aorta — is the gold-standard arterial-stiffness measure. Every 1 m/s increase associates with ~14% higher cardiovascular event risk and ~15% higher all-cause mortality (Vlachopoulos 2010 meta-analysis of 17 cohorts). Arteries stiffen because elastin fibres degrade and aren't replaced, collagen cross-links via advanced glycation end-products, and calcium deposits in the medial layer (Mönckeberg's sclerosis). The K2-MK-7 mechanism is direct: matrix Gla protein (MGP) needs vitamin-K-dependent γ-carboxylation to inhibit arterial calcification — without K2, MGP stays inactive and calcium ends up in the wrong tissue.

Targeted by: D3 + K2 MK-7 (Knapen 2015 — 180 mcg MK-7 over 3 years reduced arterial stiffness in 244 postmenopausal women; Maresz 2015 calcium-direction logic), Spermidine (Eisenberg 2016 cardiac autophagy), Quercetin (vascular-smooth-muscle senolytic component of D+Q protocol).

3. Oxidised LDL and atherogenesis

Native LDL is not particularly atherogenic; oxidised LDL is. Once LDL particles enter the arterial intima and get oxidised by reactive oxygen species, macrophages engulf them via scavenger receptors and become foam cells. Foam cells aggregate into fatty streaks, then fibrous plaques. The rate-limiting step for most people is the oxidation, not the LDL concentration per se — which is why antioxidant cofactors and inflammation control matter alongside lipid management.

Targeted by: Berberine (Yin 2008 vs metformin head-to-head — comparable HbA1c and triglyceride reduction; Dong 2013 meta — LDL-C and triglyceride reduction), CoQ10 / Ubiquinol (lipid-soluble antioxidant resident in LDL particles, protects from oxidation), Alpha-Lipoic Acid (regenerates oxidised vitamin C, vitamin E, glutathione, and CoQ10), Quercetin (Egert 2009 oxLDL reduction), Resveratrol, Curcumin, Pterostilbene (Riche 2014 — lipid lowering trial).

4. Mitochondrial bioenergetic decline

The heart never stops working. A 70-year-old has contracted their heart roughly 2.5 billion times. That contraction is fueled by ATP, which is produced by mitochondria, which decline in number, copy number, and function with age. NAD+ — the obligate cofactor for the entire respiratory chain and for sirtuin signalling — drops by an estimated 40–60% between ages 30 and 70. Cardiac CoQ10 levels at age 80 are about half what they are at age 30. The Q-SYMBIO trial (Mortensen 2014, JACC) randomised 420 advanced heart-failure patients to 300 mg/day CoQ10 or placebo for two years. The CoQ10 arm had a 43% reduction in major adverse cardiovascular events and a 42% reduction in all-cause mortality.

Targeted by: CoQ10 (Q-SYMBIO, Mortensen 2014), NR (Nicotinamide Riboside) (Martens 2018 Nature Communications — 6 weeks of 1000 mg NR reduced systolic blood pressure by ~10 mmHg in stage-1 hypertensives and reduced aortic stiffness; Brakedal 2022 NADPARK), Pure NMN 500mg + NMN 1000mg (NAD+ restoration), Liposomal NAD+ 1000mg, Urolithin A (mitophagy — clearing damaged mitochondria), PQQ (PGC-1α-driven mitochondrial biogenesis), Taurine (mitochondrial tRNA cofactor).

5. Chronic low-grade inflammation ("inflammaging")

hsCRP, IL-6, and TNF-α drift upward with age. The CANTOS trial (Ridker 2017, NEJM) used canakinumab — a monoclonal antibody against IL-1β — and reduced cardiovascular events by 15% even with no change in LDL. Inflammation is upstream of plaque rupture, the proximal cause of most heart attacks. Senescent cells secrete a pro-inflammatory cocktail (the SASP — senescence-associated secretory phenotype) that drives this. Polyphenol and senolytic-pulse strategies target the source rather than just the downstream marker.

Targeted by: Curcumin (Sahebkar 2014 meta — CRP reduction across 9 trials), Quercetin (D+Q protocol — Hickson 2019, Justice 2019), Resveratrol (NF-κB inhibition), Omega-3 (resolvins and SPMs — specialised pro-resolving mediators), Spermidine (autophagy clears damaged organelles before they trigger inflammation).

Clinical evidence — the cardiovascular trials behind each compound

Trial summaries above are condensed — full citations link out from the per-product pages. The general pattern: omega-3, K2, CoQ10, and magnesium have the strongest hard-endpoint evidence (mortality, MACE). Taurine, NR, and curcumin have strong mechanism-plus-marker evidence. Spermidine has the strongest dietary-cohort longitudinal signal.

The cardiovascular longevity stack — every product, what it does, what dose is trial-validated

Foundational trio (everyone over 40)

• Omega-3 Fish Oil 2000 mg | High EPA/DHA: The most-replicated cardiovascular supplement of the last 30 years. AHA Science Advisory recommends ≥1 g/day for established heart disease. JELIS, GISSI, REDUCE-IT, and the 2019 Hu et al. meta-analysis (n=127,000) all converge on event reduction. Two softgels = 2 g combined EPA+DHA in re-esterified triglyceride (rTG) form, IFOS-grade purity, TOTOX-tested, anchovy/sardine sourced. Trial-validated dose: 1–2 g/d for general; 4 g/d if triglycerides >200 mg/dL (REDUCE-IT level).
• Vitamin D3 5,000 IU + K2 MK-7 100 mcg: The pairing matters. D3 alone increases calcium absorption — without K2-MK-7, that calcium can deposit in arteries instead of bones (Maresz 2015). MK-7 has a serum half-life of ~3 days vs MK-4's ~1 hour, making it the only K2 form that reaches consistent γ-carboxylation of MGP and osteocalcin. Trial-validated dose: 2,000–5,000 IU D3 (target 25(OH)D 40–60 ng/mL) + 100–180 mcg MK-7.
• Magnesium Glycinate 400 mg (TRAACS): Up to 50% of US adults are sub-RDA in magnesium (NHANES). Glycinate (bisglycinate) is the most absorbed form and easiest on the gut. Mechanisms: vascular smooth-muscle relaxation, calcium-channel modulation, cofactor for >300 ATP-dependent enzymes. Trial-validated dose: 300–500 mg/d elemental for BP and sleep; 8–12 weeks for full effect.

Heart-output and statin-co-therapy layer

• CoQ10 400 mg: Statins inhibit HMG-CoA reductase upstream of both cholesterol and CoQ10 synthesis — measured CoQ10 depletion of 30–40% within months of starting (Folkers 1990). Q-SYMBIO trial (Mortensen 2014) showed 300 mg/d cut MACE by 43% in advanced heart failure. KISEL-10 showed 200 mg + selenium cut CV mortality by 54% over 4 years in healthy elderly. Trial-validated dose: 100–200 mg/d general support; 300–400 mg/d for heart failure or active statin therapy.
• Taurine 1000 mg: Plasma taurine drops ~80% from age 5 to 60 (Singh 2023 Nature). Mouse healthspan extended ~10% with restoration. Beyranvand 2011 — improved exercise capacity in heart failure. Schaffer 2018 — mitochondrial-tRNA cofactor essential for cardiac mitochondrial protein synthesis. Trial-validated dose: 1.5–3 g/d for cardiac function; 1 g/d general baseline.

Cellular-renewal layer (NAD+, sirtuin, autophagy, mitophagy)

• Nicotinamide Riboside (NR) Hard Capsules: Martens 2018 Nature Communications — 1,000 mg/d for 6 weeks dropped systolic BP by ~10 mmHg in stage-1 hypertensives and reduced aortic stiffness. Brakedal 2022 NADPARK — NR raised CSF NAD+ in Parkinson's patients. Trial-validated dose: 300–1,000 mg/d.
• Pure NMN 500 mg / NMN 1000 mg Double Strength: Yoshino 2021 (Science), Liao 2021, Yamaguchi 2024 — dose-dependent walking-speed, grip-strength and insulin-sensitivity gains across 250–900 mg. Stack with TMG to neutralise the methylation tax. Trial-validated dose: 250–1,000 mg/d.
• Liposomal NAD+ Ultimate 1000 mg: Phospholipid encapsulation for direct NAD+ delivery. Use when ceiling-loading the NAD+ pool alongside an NMN/NR base.
• Resveratrol 600 mg: Trans-resveratrol, the active anomer. SIRT1 activator (Howitz 2003), eNOS upregulator (Wallerath 2002), SIRT3 substrate. Movahed 2013 — 1 g/d HbA1c, SBP, LDL improvement. Trial-validated dose: 250–1,000 mg/d.
• Pterostilbene 100 mg: Methoxylated cousin of resveratrol with ~80% oral bioavailability vs ~20% for resveratrol. BBB-penetrant. Riche 2014 — lipid lowering at 250 mg/d (note: higher arm raised BP modestly — not first-line for hypertensives, watch the data). Trial-validated dose: 100–250 mg/d.
• Spermidine 10 mg: Eisenberg 2016 Nature Medicine — dietary spermidine in the Bruneck cohort linked to a 40% lower all-cause mortality at 20 years. Kiechl 2018 EPIC — replicated. Mechanism: cardiac autophagy + eIF5A hypusination. Dose: 1–10 mg/d (catalog gives 10 mg per cap, towards higher trial range).
• Urolithin A 500 mg: PINK1/Parkin-driven mitophagy. Clears damaged mitochondria before they leak ROS into cardiomyocytes. Andreux 2019 — first human safety + mechanism trial. Singh 2022 JAMA Network Open — Mitopure muscle endurance. About 40% of adults can convert ellagitannins to urolithin A endogenously; the other 60% need direct supplementation.
• PQQ 20 mg (BioPQQ): Pyrroloquinoline quinone — Chowanadisai 2010 — drives PGC-1α-mediated mitochondrial biogenesis (the inverse of mitophagy: building NEW mitochondria). Stack with Urolithin A as the renewal pair (clear + build).

Lipid and inflammation layer

• Curcumin 1000 mg + BioPerine: 95% standardised curcuminoids. Sahebkar 2014 meta — 6.4 mg/L hsCRP reduction. Akazawa 2012 — endothelial function additive to exercise. The piperine adjunct multiplies oral bioavailability ~2,000% (Shoba 1998).
• Quercetin 500 mg + BioPerine: Egert 2009 — oxLDL reduction. Hickson 2019 + Justice 2019 — D+Q senolytic protocol component. SCAP-pathway lipid metabolism. Modulates p16INK4a-positive senescent vascular smooth-muscle cells.
• Alpha-Lipoic Acid 600 mg: The "universal antioxidant" — water-and-lipid soluble, regenerates oxidised vitamin C, vitamin E, glutathione and CoQ10. Mittermayer 2009 — 600 mg/d improved FMD in metabolic syndrome. Heavy-metal chelator. AMPK activator.
• Berberine HCl 500 mg: AMPK pathway agonist — same target metformin hits. Yin 2008 head-to-head vs metformin: comparable HbA1c reduction, better triglyceride effect. Dong 2013 meta: LDL-C −0.65 mmol/L, triglycerides −0.50 mmol/L. Trial-validated dose: 500 mg 2–3× daily with meals.
• TMG 1000 mg (Trimethylglycine): Olthof 2005 PLOS Med meta — 3 g/d dropped homocysteine ~12%. Mandatory adjunct at high NMN/NR doses (which can drain methyl groups via NNMT). Hcy >15 µmol/L is an independent CV mortality predictor in most cohorts.

How to actually start — three protocol tiers

Tier 1 — first-time supplement buyer / general 40+ baseline

Goal: Cover the highest-evidence, highest-deficiency-rate categories first. Three bottles, ~$1.50/day equivalent.

1. Omega-3 2000 mg — 2 softgels with breakfast (helps absorption, reduces fish-burp).
2. D3 5,000 IU + K2 MK-7 100 mcg — 1 softgel with the same fatty meal (D3 and K2 are both fat-soluble).
3. Magnesium Glycinate 400 mg — 2 capsules 60–90 min before bed. Doubles as a sleep upgrade.

What to expect: Sleep quality improvement in 1–2 weeks (magnesium). Triglycerides and hsCRP shift visibly at the next blood panel (8–12 weeks). 25(OH)D rise to target range in 8–16 weeks. Arterial-stiffness changes are slower — expect to see them at the 12-month mark on a follow-up cardiac imaging panel.

Tier 2 — 50+ or on a statin

Add to Tier 1:

4. CoQ10 400 mg — 1 softgel with breakfast. Mandatory if you're on any statin. Take with a fatty meal — CoQ10 is fat-soluble.
5. Taurine 1000 mg — 1–2 capsules with food.

What to expect: Statin-induced muscle complaints often soften within 2–4 weeks of starting CoQ10 (anecdotal but common). Exercise capacity improvement on taurine in 2–4 weeks if baseline-low.

Tier 3 — full longevity protocol

Add to Tier 2 over weeks 8–12:

6. Spermidine 10 mg — daily.
7. Pure NMN 500 mg or NMN 1000 mg — morning, fasted preferred.
8. TMG 1000 mg — pair with NMN to neutralise the methylation tax.
9. Resveratrol 600 mg — with morning fats (fat-soluble, low oral bioavailability).
10. Curcumin + BioPerine — 1–2 caps with meals.

What to expect: The tier-3 layer is about the slope of biological aging more than acute markers. Expect plasma NAD+ to roughly double at 30–60 days (Yoshino 2021 / Pencina 2023 patterns). Arterial-stiffness improvements measured at 6–12 months. Inflammation markers (hsCRP, IL-6) shift in 8–12 weeks if elevated at baseline.

Stacking guide — pairing the cardiovascular stack with other protocols

With the NAD+ / NMN protocol

NMN/NR raise NAD+, which fuels SIRT1 and SIRT3 — both have direct cardiovascular roles (eNOS regulation, mitochondrial biogenesis). The combination amplifies. Stack: NMN + Resveratrol + TMG + cardiovascular foundation. See the NMN collection for protocol-A vs protocol-B dose selection.

With the Senolytic protocol

Vascular smooth-muscle senescence drives a portion of arterial stiffness. The D+Q (dasatinib + quercetin) protocol pulses out p16INK4a-positive cells. Quercetin + Fisetin in monthly pulses. See Senolytics.

With the Mitochondrial Renewal protocol

Cardiomyocytes have the highest mitochondrial density of any tissue (~30% of cell volume). The mitophagy/biogenesis pair: Urolithin A (clears damaged) + PQQ (builds new) + CoQ10 (cofactor). See Mitochondrial Renewal.

With the Foundational Health protocol

Three of the cardiovascular foundation (Omega-3, D3+K2, Magnesium) are also the spine of Foundational Health. The cardiovascular stack and foundational stack overlap by design — start with foundational and the cardiovascular layer is mostly already in place.

With the Brain & Cognitive Longevity protocol

The cerebrovascular and coronary systems share endothelium and follow nearly identical aging curves. Omega-3, Curcumin, NAD+ precursors, Spermidine, PQQ all feature in both. See Brain & Cognitive Longevity.

With the Metabolic protocol

Lipids, glucose and arterial health are coupled. Berberine for AMPK; ALA for insulin sensitivity; Resveratrol/Pterostilbene for both layers. See Metabolic.

Week-by-week — what to expect on a complete cardiovascular stack

The non-supplement non-negotiables

The supplement stack works alongside — never instead of — the four interventions with the largest cardiovascular effect sizes:

1. Don't smoke. Quitting smoking yields ~50% CV-event-rate reduction at 3–5 years post-cessation (Critchley 2003) — bigger than any single supplement.
2. ~150 minutes / week of zone-2 cardio plus 2 strength sessions. Endothelial function correlates with weekly active minutes; arterial stiffness correlates inversely with VO2max.
3. Sleep 7–9 hours. Short sleep (<6h) drives BP, IL-6 and atherogenesis. Magnesium glycinate + glycine support sleep architecture (see Glycine 1500 mg).
4. Treat hypertension, lipids, and glucose with your physician. If you're on a statin, ACE-inhibitor, beta-blocker, or anticoagulant, those drugs are doing most of the work — supplements are adjunctive. Tell your doctor what you're taking. Many of the compounds here have real interactions (see below).

Drug interactions and contraindications — read this

• Anticoagulants (warfarin, DOACs, aspirin) + Omega-3 at >3 g/d: Real bleeding-risk additivity. Stop 7 days before surgery. Discuss with your prescriber before starting at >1 g/d.
• Warfarin + Vitamin K2: K2 antagonises warfarin. INR can shift. If you're on warfarin, work with your prescriber — many will adjust warfarin dose to allow K2; do not start unilaterally.
• Statins + CoQ10: Statins deplete CoQ10. CoQ10 supplementation is generally encouraged here, not contraindicated — but tell your physician.
• Berberine + glucose-lowering medication (metformin, sulfonylureas, insulin): Hypoglycaemia risk. Coordinate with prescriber. Berberine also inhibits CYP3A4 and P-gp — review every other prescription drug for interaction.
• Resveratrol, Curcumin, Quercetin: All modulate CYP3A4. Major interactions with chemotherapy, immunosuppressants (tacrolimus, cyclosporine), some antifungals, some antivirals, and warfarin.
• NMN/NR + ACE-inhibitors / ARBs: Martens 2018 saw additional BP drop on NR — if your BP is well-controlled, monitor for hypotension when starting.
• Magnesium + tetracycline / fluoroquinolone antibiotics: Take 2 hours apart — magnesium chelates these antibiotics and reduces absorption.
• Spermidine (wheat-germ-derived): Contains residual gluten — coeliac disease is a contraindication.
• Pregnancy and breastfeeding: Most longevity compounds (NMN, NR, Spermidine, Resveratrol, Berberine, high-dose Curcumin) lack pregnancy safety data and should be avoided. Foundational nutrients (Omega-3, D3, K2 within RDA range, Magnesium) are generally safe under prenatal-care guidance.

Who this is for — and who it isn't

Strong fit

• Adults 40+ with elevated lipids, BP, hsCRP, or fasting glucose at the lab.
• Anyone on a statin (CoQ10 is essentially mandatory).
• Family history of premature CAD, sudden cardiac death, or heart failure.
• Post-menopausal women (K2 + D3 for arterial calcification + bone density combined).
• Endurance athletes 40+ (CoQ10, taurine, omega-3 for cardiac output and recovery).
• Anyone with a high coronary calcium score actively trying to slow the slope.

Less obvious fit

• People with great labs but a strong family history — start the foundation early; the slope of risk matters.
• People in their 30s building a healthspan baseline before things drift — Omega-3 + D3+K2 + Magnesium make sense as a 30+ floor.
• Recently post-CV-event (post-MI, post-stent) under cardiology care — discuss with your team; many cardiologists will green-light Omega-3, D3+K2, CoQ10, magnesium, and curcumin.

Not a fit

• Pregnancy/breastfeeding (default to your obstetric team's guidance — most of these compounds don't have pregnancy data).
• Active anticoagulation without prescriber coordination (Omega-3, K2, garlic-family compounds, high-dose Curcumin).
• Active GI bleed, recent surgery, or platelet disorders.
• Severe CKD (some compounds renally cleared; coordinate with your nephrologist).
• Anyone expecting a single supplement to replace a statin, BP drug, or anticoagulant. The supplement layer adds; it doesn't replace.

Quality standards — what we built into every cardiovascular SKU

• cGMP, FDA-registered facility manufacturing. NSF/USP-tier processes.
• HPLC potency on every batch. Label claim verified, not estimated.
• Heavy-metal panel on every fish-oil and herbal-extract batch (lead, arsenic, cadmium, mercury) at California Prop 65 limits.
• TOTOX testing on Omega-3 (oxidation state — most consumer fish oil fails this; ours doesn't).
• Trans-isomer verification on Resveratrol and Pterostilbene (the active anomer is trans; the cis form is mostly inactive).
• Branded-ingredient sourcing where it matters: BioPerine for piperine, TRAACS for magnesium glycinate, BioPQQ for PQQ, Niagen-class for NR, Mitopure-grade for Urolithin A.
• No proprietary blends. Every active ingredient and dose is on the label.
• No titanium dioxide, no magnesium stearate, no PEGs.
• HPMC (vegan) capsules. Bovine gelatin only where the trial format used it (a small minority of softgel SKUs).
• 24-month shelf life verified by accelerated stability testing.

Read the full Quality standards page and the Ingredient sourcing page for batch-level detail.

Frequently asked — cardiovascular-specific

Can I take all 14 of these together?

You can. Most longevity-protocol-experienced users converge on a 8–12 SKU stack within a year. The only stacking caveat is the methylation tax of high-dose NMN/NR — pair with TMG. And mind the bleeding-risk additivity of Omega-3 + Curcumin + Quercetin + Resveratrol if you're on an anticoagulant.

I'm on a statin. What's the priority order?

(1) CoQ10 — non-negotiable if statins are part of your regimen. (2) Omega-3 — synergistic with statins; REDUCE-IT and JELIS were both on statin background. (3) D3+K2 — particularly for the K2 arterial-calcification arm. (4) Magnesium — corrects deficiency that statin-related muscle complaints can mask. Consider Curcumin and Berberine to address the inflammatory and metabolic arms statins don't directly hit.

Will Berberine replace metformin?

Yin 2008 showed comparable HbA1c reduction at 3 months in T2DM. That's mechanistic equivalence on a single metric — not regulatory equivalence. Metformin has 60+ years of mortality data, an FDA approval, and a Cochrane review base behind it. If your physician has prescribed metformin, do not substitute. Berberine is reasonable as adjunctive for prediabetes, metabolic syndrome, or as a glucose tool when metformin is not appropriate. Discuss with the prescriber.

How long until my lipid panel changes?

Berberine: 8–12 weeks (Dong 2013 timing). Omega-3: triglycerides shift in 4–8 weeks; LDL particle quality (small-dense → large-buoyant) takes longer. Pterostilbene: 6–8 weeks (Riche 2014). Plant-sterol-free diet, soluble fibre, and statin therapy will dwarf the supplement effect on raw LDL-C. Use supplements where they're doing what statins don't — inflammation, oxidation, endothelial function, mitochondrial output.

Vitamin D3 with or without K2?

With. Always. D3 alone increases calcium absorption from the gut. Without K2 to direct that calcium into bones (via osteocalcin γ-carboxylation) and away from vasculature (via matrix Gla protein γ-carboxylation), the calcium can deposit in arteries instead. Maresz 2015 (Integrative Med) lays out the calcium-direction logic. We co-formulate the two for that reason.

Why MK-7 over MK-4?

Serum half-life. MK-7 = ~3 days. MK-4 = ~1 hour. MK-7 maintains continuous γ-carboxylation activity at a once-daily dose. MK-4 needs 3× daily redosing at 5–15 mg per dose to match the effect. The Knapen 2015 trial that showed arterial-stiffness reduction over 3 years used 180 mcg/d MK-7.

Is the Q-SYMBIO trial relevant if I don't have heart failure?

The MACE/mortality endpoint comes from advanced (NYHA III–IV) heart failure. Q-SYMBIO is the strongest evidence in that population. For lower-severity populations, the relevant CoQ10 evidence is KISEL-10 (mortality reduction in healthy elderly with selenium adjunct) and the cardiac-tissue CoQ10 pharmacology (depletion with statins, age-decline). The 100–200 mg/d general-support dose is reasonable for healthy adults; the 300–400 mg/d Q-SYMBIO dose is what you'd use if there were any heart-failure or statin-intensive context.

How does the Singh 2023 taurine paper apply to me?

Singh 2023 (Nature) was the largest taurine-and-aging study to date — combining cohort data showing plasma taurine declines ~80% from age 5 to 60, with mouse and primate intervention data showing healthspan extension on restoration. It's mechanistic + cohort + animal-intervention level evidence — not yet a controlled RCT in humans. The cardiovascular intervention RCTs (Beyranvand 2011, Schaffer 2018) provide the orthogonal supporting data. Reasonable case to take 1–3 g/d at 50+; conservative case to wait for bigger human RCTs.

Does Spermidine actually do anything in the dose I can take by mouth?

The Eisenberg 2016 / Kiechl 2018 cohort signals are at dietary intakes (top quintile ~25 mg/d from food). 10 mg/d wheat-germ-derived spermidine sits in the meaningful dietary-intake range. The mechanism (cardiac autophagy, eIF5A hypusination) is solid. The replicated cohort signal across Bruneck and EPIC (n >23,000) is unusual for a dietary supplement.

What about garlic, hawthorn, hibiscus?

Garlic (aged extract): modest BP and LDL effect, kalpa- and trial-validated. Hawthorn: NYHA II heart-failure adjunct evidence, smaller signal. Hibiscus: small SBP effect (~5 mmHg). All reasonable, none in our current catalog. We focus on the compounds with the deepest replicated mechanism + endpoint evidence.

Niacin (Vitamin B3) — yes or no?

The HPS2-THRIVE and AIM-HIGH trials showed niacin added to statin failed to reduce events and increased some adverse effects (Boden 2011, HPS2-THRIVE 2014). We do not promote high-dose niacin for lipid management. Methyl-group-conserving NAD+ precursors (NMN, NR) are different molecules and use a different pathway — they don't carry the niacin flush or HPS2-THRIVE history.

What if I don't see anything happen in 4 weeks?

You won't. Cardiovascular markers are slow. Lipids: 8–12 weeks. 25(OH)D: 8–16 weeks. PWV/CIMT: 6–24 months. The fastest signal you should expect is on sleep (magnesium, glycine) and exercise recovery (omega-3, taurine, CoQ10) within 2–4 weeks. The rest is on the timeline of the underlying biology, not the marketing copy of the bottle.

Do you have a 30-day money-back guarantee?

Yes — see Guarantee and Refund policy. The honest framing: 30 days is enough time to confirm the magnesium-and-sleep effect, GI tolerance, and that the bottles are what they say they are. It's not enough time to see lipid or arterial-stiffness shifts. Plan for a 12-week minimum to evaluate the cardiovascular layer; the guarantee is for fit-and-quality, not for slow biology.

Reading list

• CoQ10 and statins — the cofactor your statin depletes
• Foundational health — the 7 daily nutrients underneath every stack
• Longevity supplements after 40 — what changes
• NMN vs NR — which NAD+ precursor actually works better
• Full Protocol Library

Where to next

This collection is the cardiovascular vertical. The rest of the site:

• Our Science — the López-Otín hallmarks-of-aging framework that organises the catalog.
• Protocols — the six house protocols (Cellular, Senolytic, Mitochondrial, Skin, Brain, Cardiovascular).
• Getting Started — a guided first-bottle decision walkthrough.
• How it works — sourcing, dosing, manufacturing.
• Quality standards — cGMP, COA, third-party testing detail.
• Ingredient sourcing — where every active comes from.
• Contact — pre-purchase questions, drug-interaction reviews, bulk and clinical inquiries.
• 30-day Guarantee.

Sister collections:

• Foundational Health — D3, K2, magnesium, omega-3 (the cardiovascular foundation overlap).
• NMN Supplements — entry into the cellular-renewal layer.
• NAD+ Family — full NAD+ ecosystem.
• Senolytics — fisetin and quercetin for vascular smooth-muscle senescence.
• Mitochondrial Renewal — Urolithin A + PQQ + CoQ10.
• Brain & Cognitive Longevity — overlapping endothelial mechanisms.
• Metabolic — glucose, lipids, insulin sensitivity.
• Longevity Essentials — the curated essentials lineup.
• All Products.

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. If you have cardiovascular disease, are on anticoagulants, blood-pressure medication, statins, glucose-lowering medication, immunosuppressants, or chemotherapy, talk to your doctor before starting any supplement. Cardiovascular medications are doing real work — supplements are adjunctive, not replacement. Do not stop or modify a prescribed cardiovascular medication based on supplement use without your physician's input. If you experience chest pain, sudden shortness of breath, syncope, or one-sided weakness or speech disturbance, call emergency services — those are time-critical symptoms that supplements do not address.